Alzheimer’s disease affects nearly 6 million Americans. It’s the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older, and the problem is only getting worse as the country ages: in 2016, 49 million adults living in the United States were […]
Trending News
PointClickCare Acquires CPSI Subsidiary, American HealthTech
PointClickCare Technologies, a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights at every stage of the patient healthcare journey, today announced the acquisition of American HealthTech, Inc. (AHT), a subsidiary of Computer Programs and Systems, Inc. and a leading provider of electronic health record (EHR) solutions […]
Oxford Nanopore Technologies and Saphetor Announce a New Partnership to Deliver Tertiary Analysis for Comprehensive Interpretation of Nanopore Sequencing
Oxford Nanopore Technologies plc, a company providing next-generation nanopore-based molecular sensing technology, and Saphetor, a next-generation sequencing data analysis company, today announce a new partnership to support supports comprehensive analysis of nanopore sequencing data and enables comprehensive analysis of nanopore sequencing data. -end of workflow. The collaboration with Saphetor will […]
Verily and OneOncology Announce Collaboration to Advance Cancer Research
Verily, a precision medical technology company of Alphabet, and OneOncology, the national platform for independent oncology practice, have established a strategic partnership that enables more effective clinical trials. As part of the agreement, Verily will integrate the clinical trial management software (CTMS) platform, SignalPath, with all operations in the OneOncology […]
ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing
ADARx Pharmaceuticals, Inc., a clinical-stage biotech company developing next-generation RNA-based therapies, today announced the successful conclusion of its over-subscribed Series C funding. value of 200 million dollars. The funding was led by Bain Capital Life Science and TCGX and includes new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare […]
Henry Schein Acquires a Majority Interest in Large Practice Sales LLC, a Leading Transaction Advisory Services Business
Henry Schein, Inc., the world’s largest provider of healthcare products and solutions to in-office medical and dental practitioners, today announced the acquisition of controlling interest in Large Practice Sales LLC (LPS), a leading advisor for their independent dental practices. sell or partner with larger general practitioners and dental professionals. Headquartered […]
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
QuidelOrtho Corporation, a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2023 IMV ServiceTrak Awards for the sixth consecutive year. The […]
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
Genentech, a member of the Roche Group, announced today that data from its ophthalmology portfolio will be featured in 25 abstracts at the American Society of Retina Specialists (ASRS) Annual Meeting (ASRS). ) 2023, taking place from July 28 to August 1 in Seattle, WA. The data reinforce the depth […]
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Zolbetuximab
Astella Pharma Inc. announced that the European Medicines Agency (EMA) has accepted regulatory review of the company’s Marketing Authorization (MA) Application for zolbetuximab, an experimental first-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with locally advanced, unresectable or metastatic gastric or esophageal adenocarcinoma (GEJ) whose […]
KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer
KSQ Therapeutics, Inc., a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISRomics® discovery platform, today announced that it has entered into a worldwide licensing and partnership agreement with Roche to develop and commercialize the KSQ-4279. KSQ-4279 is a selective, potent, first-class small molecule inhibitor of USP1, a protein […]